T-Cell Redirecting Therapies Reshape the Future of Lung Cancer Treatment
核心洞察
Tarlatamab is the only T-cell redirecting modality with traditional FDA approval in lung cancer (搜索), showing an overall survival of 13.6 months versus 8.3 months in the DeLLphi-304 trial.
Tumor-infiltrating lymphocyte (TIL) therapy is the most mature adoptive approach in non-small cell lung cancer (搜索), achieving a 64.3% objective response rate with pembrolizumab in immune checkpoint inhibitor-naive disease.
CAR-T and TCR-T therapies remain at an early proof-of-concept stage, with global CAR-T objective response rates still under 10% in lung cancer (搜索).
T-cell redirecting therapies are reshaping the treatment landscape for lung cancer (搜索), according to a comprehensive analysis of clinical trials published in Frontiers in Immunology. The review, authored by Jiahe Zhao, Ayrton Bangolo, Lili Zhang, and Martin Gutierrez, with mentorship from Miguel Gonzalez Velez, Medical Oncologist at John Theurer Cancer Center, University Medical Center, evaluates the current state and future potential of these emerging immunotherapeutic approaches.
The analysis highlights that Tarlatamab stands as the only T-cell redirecting modality to have received traditional FDA approval in lung cancer (搜索). In the DeLLphi-304 trial, Tarlatamab demonstrated an overall survival of 13.6 months compared with 8.3 months, underscoring its clinical benefit in this setting.
Among adoptive cell approaches, tumor-infiltrating lymphocyte (TIL) therapy represents the most mature strategy in non-small cell lung cancer (搜索) (NSCLC). The review reports a 64.3% objective response rate (ORR) when TIL therapy was combined with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-naive disease, positioning TIL as a promising avenue for earlier-line treatment.
In contrast, chimeric antigen receptor T-cell (CAR-T) and T-cell receptor-engineered T-cell (TCR-T) therapies remain at an early proof-of-concept stage. The review notes that the global CAR-T objective response rate in lung cancer (搜索) remains under 10%, reflecting the substantial hurdles these approaches still face in solid tumor indications.
Despite these advances, the authors emphasize that significant challenges remain to be overcome in the application of cellular therapies to lung cancer (搜索). The review underscores the need for continued investigation to address the biological and clinical barriers limiting broader adoption of these T-cell redirecting strategies.